CN110604296A - Health buccal tablet containing natamycin and preparation method thereof - Google Patents
Health buccal tablet containing natamycin and preparation method thereof Download PDFInfo
- Publication number
- CN110604296A CN110604296A CN201910968051.6A CN201910968051A CN110604296A CN 110604296 A CN110604296 A CN 110604296A CN 201910968051 A CN201910968051 A CN 201910968051A CN 110604296 A CN110604296 A CN 110604296A
- Authority
- CN
- China
- Prior art keywords
- parts
- natamycin
- powder
- buccal tablet
- tabletting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010298 natamycin Nutrition 0.000 title claims abstract description 36
- 239000004311 natamycin Substances 0.000 title claims abstract description 36
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 title claims abstract description 36
- 229960003255 natamycin Drugs 0.000 title claims abstract description 36
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 23
- 229940046011 buccal tablet Drugs 0.000 title claims abstract description 21
- 230000036541 health Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000843 powder Substances 0.000 claims abstract description 34
- 244000288157 Passiflora edulis Species 0.000 claims abstract description 32
- 235000000370 Passiflora edulis Nutrition 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 240000008086 Echinocereus enneacanthus Species 0.000 claims abstract description 28
- 235000010837 Echinocereus enneacanthus subsp brevispinus Nutrition 0.000 claims abstract description 28
- 235000006850 Echinocereus enneacanthus var dubius Nutrition 0.000 claims abstract description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 28
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 15
- 239000008101 lactose Substances 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 14
- 239000007779 soft material Substances 0.000 claims abstract description 14
- 235000012907 honey Nutrition 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 16
- 238000007873 sieving Methods 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 18
- 208000002925 dental caries Diseases 0.000 description 13
- 230000001276 controlling effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000000214 mouth Anatomy 0.000 description 10
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 206010043268 Tension Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- -1 sterol compounds Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 240000000559 Albizia odoratissima Species 0.000 description 1
- 235000011438 Albizia odoratissima Nutrition 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 208000004042 dental fluorosis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005672 tetraenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The health buccal tablet containing natamycin comprises, by mass, 300 ~ 550 parts of passion fruit, 200 ~ 500 parts of pitaya flower, 1 ~ 5 parts of natamycin, 30 ~ 70 parts of xylo-oligosaccharide, 40 ~ 80 parts of honey and 170 ~ 300 parts of tabletting auxiliary materials, wherein the composition extract and the fruit powder are prepared by uniformly mixing the fruit powder, the natamycin and xylo-oligosaccharide powder by weight, adding the honey, the lactose and the composition extract A to prepare soft material particles, drying the soft material particles, adding magnesium stearate to uniformly tabletting, and drying the tabletting.
Description
Technical Field
The invention relates to an oral care potion, in particular to a natamycin-containing health buccal tablet and a preparation method thereof.
Background
Dental caries is a progressive lesion of hard tooth tissue caused by the compounding and acting of various factors in the oral cavity, and is represented by the evolution process of inorganic demineralization and organic matter decomposition from color change to substantial lesion formation along with the development of the course of disease. Dental caries is a bacterial disease and therefore it can be secondary to pulpitis and periapical inflammation and can even cause inflammation of the alveolar bone and jaw bone. The secondary infection of dental caries can form focus, and can cause or add other diseases of the whole body such as arthritis, cardia periostitis, chronic kidney and various eye diseases. Dental caries should be mainly prevented for health care.
Fluoride anticariogenic has been known for over 40 years and includes drinking water with fluorine, fluorine-containing milk or fluorine-containing salt, topical fluorine (including fluorine)
Fluorine toothpaste, fluorine-containing gel, fluorine-containing mouth wash) and the like, and fluoride can reduce the caries rate of people to different degrees, so that fluoride is known as an effective caries prevention measure in the world currently. The oral medical community has proposed that fluoride anticaries is one of the major achievements in oral preventive medicine in the 20 th century, but the measurement of fluoride on human body's profit and disadvantage has been the subject of controversy in the oral medical field so far. It appears that the use of fluorine formulations has significant limitations, such as dental fluorosis, etc. Therefore, the search for new, safe and effective fluorine-free preparations is receiving increasing attention from researchers in the field of caries prevention and treatment.
At present, some antibacterial agents are used for preventing and treating dental caries, and a long-term use of broad-spectrum antibacterial agents and chemical synthetic drugs destroys the ecological balance of the oral cavity while removing pathogenic bacteria in the oral cavity. Meanwhile, long-term use of antibacterial drugs may cause side effects such as edema, hypertension, induction and aggravation of infection, and the like. Moreover, antibiotic drugs are susceptible to drug resistance when applied topically, and long-term topical application can cause dysbacteriosis and fungal infection. This is particularly true in children. If the traditional Chinese medicine with antibacterial effect is used, the ecological balance of the oral cavity can not be damaged while the pathogenic bacteria are inhibited. Meanwhile, the natural returning and the green therapy are accepted by more people due to the special curative effect and safety of the traditional Chinese medicine. In recent years, the research on the pharmacology and mechanism of applying traditional Chinese medicine to the prevention and treatment of dental caries has been paid attention and attention by scholars at home and abroad, and has made a better progress. Therefore, the development of a convenient and practical medicament for preventing and treating the decayed teeth has become necessary.
The passion fruit has the effects of exciting and strengthening after being used as a medicine. The pulp is juicy, and can be added with calcium bicarbonate and sugar to make aromatic and delicious beverage, or added into other beverage to improve quality of beverage. Although the nutritional value of the passion fruit is high, the passion fruit developed at present is only used as an additive for making beverages or a taste modifier for other products, the utilization rate of the passion fruit is low at present, only the inner pulp is utilized, and the outer part of the shell is discarded as garbage. At present, no product which completely develops the medicinal and nutritional values of the passion fruit exists, and no buccal tablet which takes the passion fruit as the main raw material exists in the market.
The pitaya flower is a perennial fleshy herb climbing plant, the main edible part is a flower container, the dried product of the flower container is a good product in vegetables, and the content of the nutrient components in each 100g of the dried product of the pitaya flower is as follows: 9.570g of water, 1.812g of protein, 2.785g of crude fiber, 1.547g of ash, 961.27mg of calcium and 328.45mg of phosphorus, at least 13 amino acids are contained, and the amino acids comprise a plurality of amino acids essential to human bodies. And also contains Cu, N, Cr, Cd, Ca, Zn and other elements which have important effects on human body. The pitaya flower not only can be eaten by people as a food material, but also has rich medicinal efficacy. The traditional Chinese medicine believes that the medicine has sweet and cool nature and taste, enters lung and has the effects of clearing heat and phlegm, removing accumulated heat, clearing phlegm-fire and the like. The pitaya flower has the effects of clearing heat and moistening lung, and has a close relation with the attribute of the pitaya flower, the pitaya flower is sweet in taste, slightly cold in nature and capable of entering lung channels, so that the pitaya flower can help to clear heat phlegm, remove accumulated heat and regulate phlegm fire, effectively moisten lung and clear lung, can help to relieve cough and reduce phlegm, has a certain auxiliary treatment effect on respiratory diseases such as cough, thick yellow phlegm bronchitis and the like, has a good relieving effect on constipation caused by vigorous heat in a body due to the heat of the pitaya flower.
Natamycin is a tetraene antibiotic extracted from NATALENSIS streptomycete, polyene is a plane macrolide ring structure, can interact with sterol compounds with high affinity, the action mechanism is that hydrophobic parts, namely double bond parts of macrolide are combined with whole sterol molecules by van der waals force to form a polyene sterol compound, the permeability of cell membranes is changed to form water pores, and important substances such as amino acid, electrolyte and the like in fungal cells are exuded, so that the fungi die. Hygiene and skin spot experiments show that natamycin has no anaphylactic reaction and is difficult to generate resistance by microorganisms; natamycin approved in 1996 in China as a food preservative for cheese, meat products, Cantonese moon cakes, surfaces of cakes, fruit juice puree, surfaces of easily mildewed food processing vessels and the like.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a natamycin-containing health buccal tablet and a preparation method thereof.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a health buccal tablet containing natamycin comprises the following raw materials, by mass, 300 36550 parts of passion fruit, 200 ~ parts of pitaya flower, 1 ~ parts of natamycin, 30 ~ parts of xylo-oligosaccharide, 40 ~ parts of honey and 170 ~ parts of tabletting auxiliary materials.
The passion fruit is superfine powder with 500 ~ 1000 meshes of fruit shell pulp and 500 ~ 1000 meshes of pitaya flower.
The tabletting adjuvant is one or more of lactose, microcrystalline cellulose, sodium carboxymethylcellulose, magnesium stearate and silica gel micropowder.
The tabletting auxiliary material comprises, by mass, 40 ~ 300 parts of lactose, 35 ~ 400 parts of microcrystalline cellulose, 3.5 ~ 15 parts of sodium carboxymethyl cellulose, 0.35 ~ 10 parts of magnesium stearate and 1 ~ 35 parts of aerosil.
The preparation method of the health buccal tablet containing natamycin comprises the following specific preparation steps:
(1) peeling the fruit shell to obtain fruit pulp, crushing the passion fruit pulp and the pitaya flower respectively, mixing, adding 60-80% ethanol for extraction for 2 times, filtering, recovering ethanol from filtrate, and concentrating to obtain an extract with a relative density of 1.10-1.15/60 ℃ to obtain a composition extract A;
(2) separating water from the separated pulp by a freeze drying technology, controlling the total content of the residual water to be between 11 and 17 percent, repeatedly crushing the dried pulp into superfine powder by crushing, and sieving by a 500-mesh sieve to obtain fruit powder B for later use;
(3) uniformly mixing the fruit powder B, the natamycin and the xylo-oligosaccharide powder in parts by weight, sieving the mixture by a 500-mesh sieve, adding the honey, the lactose and the composition extract A, continuously stirring the mixture to fully mix the raw materials, repeatedly adding the composition extract A for 3 times to prepare soft material granules, drying the soft material granules at the drying temperature of 40-50 ℃ to obtain soft material granules with the water content of 10-15%, sieving the granules by a 20-30-mesh sieve, adding the magnesium stearate in parts by weight, uniformly tabletting, drying the tablets, controlling the temperature to be 40-50 ℃, controlling the tabletting weight to be 500-800 mg, and finally locking the water content to be below 5%.
And (3) controlling the drying temperature of the passion fruit powder B extracted in the step (2) to be between-10 ℃ and-15 ℃.
The buccal tablet is prepared by concentrating the buccal tablet, can relieve sub-fatigue to the maximum extent and is convenient to carry, and the buccal tablet considers the absorptivity of mucous membranes in the oral cavity, has a better curative effect than various prepared juices, is healthier than compound juice, and contains fewer additives. The natamycin is added as a bacteriostatic agent in the oral cavity, the natamycin in the invention is added as a preservative and is used as an oral bacteriostatic agent, and the residence time of the buccal tablets in the oral cavity leaves sufficient room for the natamycin to inhibit bacteria in the oral cavity, so that the harm of the buccal tablets to teeth in the oral cavity is avoided; the invention has the advantages of low cost, suitability for industrial production, and strong sterilization and inhibition effects on natamycin, especially on candidiasis (commonly called thrush) in oral cavity. The xylo-oligosaccharide is selected in the invention in order to reduce the generation of dental caries to the maximum extent, the dental caries is caused by the erosion of oral microorganisms, particularly streptococcus, and the xylo-oligosaccharide added in the invention is not a proper action substrate of the oral microorganisms, so that the dental caries is not caused, and the growth of oral bacteria is inhibited. The addition of xylo-oligosaccharide not only increases the taste of the product, but also prevents the occurrence of dental caries, and the xylo-oligosaccharide in the invention has the outstanding characteristics of acid resistance, good thermal stability and difficult fermentation, and compared with other oligosaccharides, the xylo-oligosaccharide has very good stability. Even when heated to 100 ℃ under acidic conditions (pH = 2.5-7), the functional oligosaccharides are not substantially decomposed, while some functional oligosaccharides are easily decomposed under acidic conditions, thereby causing a decrease in the proliferation activity of bifidobacteria and losing the health-care effect.
Detailed Description
Example 1
A health buccal tablet containing natamycin comprises, by mass, 300 ~ 550 parts of passion fruit, 200 ~ 500 parts of pitaya flower, 1 ~ 5 parts of natamycin, 30 ~ 70 parts of xylo-oligosaccharide, 40 ~ 80 parts of honey, 170 ~ 300 parts of tabletting auxiliary materials, wherein the passion fruit is superfine powder with 500 ~ 1000 meshes of fruit shell pulp, the pitaya flower is superfine powder with 500 ~ 1000 meshes of 500, the tabletting auxiliary materials are one or more of lactose, microcrystalline cellulose, sodium carboxymethylcellulose, magnesium stearate and aerosil, and the tabletting auxiliary materials comprise, by mass, 40 ~ 300 parts of lactose, 35 ~ 400 parts of microcrystalline cellulose, 3.5 ~ 15 parts of sodium carboxymethylcellulose, 0.35 ~ 10 parts of magnesium stearate and 1 ~ 35 parts of aerosil.
The preparation method of the health buccal tablet containing natamycin comprises the following specific preparation steps:
(1) peeling a fruit shell to obtain a pulp, crushing the pulp of the passion fruit and the pitaya flower respectively, mixing 30 parts by mass of the pulp of the passion fruit and 200 parts by mass of the pitaya flower, adding 60-80% ethanol for extraction for 2 times, filtering, recovering ethanol from filtrate, and concentrating the filtrate to obtain an extract with the relative density of 1.25-1.40/60 ℃, thereby obtaining a composition extract A;
(2) separating water from the separated pulp by a freeze drying technology, controlling the drying temperature of passion fruit powder B to be between-10 ℃ and-15 ℃, controlling the total content of the residual water to be between 13% and 17%, repeatedly crushing the dried pulp into superfine powder by crushing, and sieving by a 500-mesh sieve to obtain fruit powder B for later use;
(3) uniformly mixing the fruit powder B, the natamycin and the xylo-oligosaccharide powder in parts by weight, sieving the mixture by a 500-mesh sieve, adding the honey, the lactose and the composition extract A, continuously stirring the mixture to fully mix the raw materials, repeatedly adding the composition extract A for 3 times to prepare soft material granules, drying the soft material granules at the drying temperature of 40-50 ℃ to obtain soft material granules with the water content of 10-15%, sieving the granules by a 20-30-mesh sieve, adding the magnesium stearate in parts by weight, and uniformly tabletting, wherein the components are in parts by weight: 220 parts of composition extract A, 300 parts of passion fruit powder B, 1.5 parts of natamycin, 55 parts of xylooligosaccharide powder, 70 parts of honey, 40 parts of lactose and 7 parts of magnesium stearate, and then tabletting is dried, the temperature is controlled to be 40-50 ℃, the tabletting weight is controlled to be 500-800 mg, and the final water content is locked below 5%.
Example 2
A health buccal tablet containing natamycin comprises, by mass, 300 ~ 550 parts of passion fruit, 200 ~ 500 parts of pitaya flower, 1 ~ 5 parts of natamycin, 30 ~ 70 parts of xylo-oligosaccharide, 40 ~ 80 parts of honey, 170 ~ 300 parts of tabletting auxiliary materials, wherein the passion fruit is superfine powder with 500 ~ 1000 meshes of fruit shell pulp, the pitaya flower is superfine powder with 500 ~ 1000 meshes of 500, the tabletting auxiliary materials are one or more of lactose, microcrystalline cellulose, sodium carboxymethylcellulose, magnesium stearate and aerosil, and the tabletting auxiliary materials comprise, by mass, 40 ~ 300 parts of lactose, 35 ~ 400 parts of microcrystalline cellulose, 3.5 ~ 15 parts of sodium carboxymethylcellulose, 0.35 ~ 10 parts of magnesium stearate and 1 ~ 35 parts of aerosil.
The preparation method of the health buccal tablet containing natamycin comprises the following specific preparation steps:
(1) peeling a fruit shell to obtain a pulp, crushing the pulp of the passion fruit and the pitaya flower respectively, mixing 50 parts by mass of the pulp of the passion fruit and 200 parts by mass of the pitaya flower, adding 60-80% ethanol for extraction for 2 times, filtering, recovering ethanol from filtrate, and concentrating the filtrate to obtain an extract with the relative density of 1.10-1.15/60 ℃ to obtain a composition extract A;
(2) separating water from the separated pulp by a freeze drying technology, controlling the drying temperature of passion fruit powder B to be between-10 ℃ and-15 ℃, controlling the total content of the residual water to be between 11 percent and 14 percent, repeatedly crushing the dried pulp into superfine powder by crushing, and sieving by a 500-mesh sieve to obtain fruit powder B for later use;
(3) uniformly mixing the fruit powder B, the natamycin and the xylo-oligosaccharide powder in parts by weight, sieving the mixture by a 500-mesh sieve, adding the honey, the lactose and the composition extract A, continuously stirring the mixture to fully mix the raw materials, repeatedly adding the composition extract A for 3 times to prepare soft material granules, drying the soft material granules at the drying temperature of 40-50 ℃ to obtain soft material granules with the water content of 10-15%, sieving the granules by a 20-30-mesh sieve, adding the magnesium stearate in parts by weight, and uniformly tabletting, wherein the components are in parts by weight: 200 parts of composition extract A, 280 parts of passion fruit powder B, 1.7 parts of natamycin, 60 parts of xylooligosaccharide powder, 65 parts of honey, 50 parts of lactose and 10 parts of sodium carboxymethylcellulose, then drying the tabletting, controlling the temperature to be 40-50 ℃, controlling the weight of the tabletting to be 500-800 mg, and finally locking the water content to be below 4%.
The pitaya flower is rich in nutrition and can well improve the immunity of a human body. The pitaya flower contains various trace elements and at least 13 amino acids, so that extremely rich nutrition can be supplemented for a body, and the body immunity can be improved by eating the pitaya flower frequently.
The content of phosphorus in the pitaya flower is high, the phosphorus is an important component forming a nervous system, the phosphorus has the effect of maintaining acid-base balance in a body and participates in fat and sugar metabolism, and the content of calcium in the pitaya flower is 961.27mg/kg, which is a good source of calcium. Calcium has good effects in forming and maintaining bones, and preventing infantile bones and osteoporosis.
The passion fruit is rich, sweet and sour, and delicious, and can promote the production of body fluid to quench thirst; refreshing, loosening bowel to relieve constipation, and preventing carcinoma of large intestine; tonifying kidney, strengthening body constitution, removing toxic substance, and caring skin; relieving alcoholism, protecting liver, and relieving fatigue; has effects in lowering blood pressure, blood sugar and cholesterol; oral ulcer, periodontitis, and pharyngolaryngitis; has effects in treating colitis and gastrointestinal diseases; regulating blood sugar, and preventing diabetes; the bone is strengthened and the osteoporosis is relieved; improving immunity, and preventing diseases. The passion fruit is a natural tranquilizer and has the effects of relaxing and calming nerves; can be used for treating insomnia, inducing natural sleep and deep sleep, and eliminating headache and dizziness; it also can relieve headache, gastralgia, frequent micturition, palpitation, muscle spasm, tetany, and pain caused by anxiety, stress, depression, and nervous tension. Lycopene in passion fruit can remove free radicals, block nitrosamine formation, and has the effects of preventing and resisting cancer, preventing cardiovascular diseases, enhancing immunity and delaying aging. Passion fruit has a complex role in the central nervous system. The nikkic acid contained in the eggplants is necessary for cell respiration and participates in a plurality of metabolic processes in the body, and the nikkic acid plays roles of resisting pellagra, preventing mental depression and the like, so people with high working and mental stress need to eat the nikkic acid regularly. The passion fruit can be used for treating insomnia, inducing natural sleep and deep sleep, and eliminating headache, dizziness and other phenomena; relieving anxiety, depression, albizia, headache, frequent micturition, and palpitation caused by nervous tension; improving muscle spasm, convulsion, and pain caused by nervous tension; relieve all discomfort caused by nervous tension and extreme anxiety; improve extreme depressed mood and excessive anxiety.
Claims (6)
1. The health-care buccal tablet containing natamycin is characterized by comprising the following raw materials, by mass, 300 ~ 550 parts of passion fruit, 200 ~ 500 parts of pitaya flower, 1 ~ 5 parts of natamycin, 30 ~ 70 parts of xylo-oligosaccharide, 40 ~ 80 parts of honey and 170 ~ 300 parts of tabletting auxiliary materials.
2. The natamycin-containing health buccal tablet as claimed in claim 1, wherein the passion fruit is ultramicro powder with a shell pulp of 500 ~ 1000 meshes 1000, and the pitaya flower is ultramicro powder with a shell pulp of 500 ~ 1000 meshes 1000.
3. The natamycin-containing health buccal tablet as claimed in claim 1, wherein the tabletting excipients are one or more of lactose, microcrystalline cellulose, sodium carboxymethyl cellulose, magnesium stearate and aerosil.
4. The natamycin-containing health buccal tablet as claimed in claim 1, wherein the tabletting excipients comprise, by mass, 40 ~ 300 parts of lactose, 35 ~ 400 parts of microcrystalline cellulose, 3.5 ~ 15 parts of sodium carboxymethylcellulose, 0.35 ~ 10 parts of magnesium stearate and 1 ~ 35 parts of aerosil.
5. The preparation method of the natamycin-containing health buccal tablet according to claim 1, 2, 3 or 4 is characterized by comprising the following steps:
(1) peeling the fruit shell to obtain fruit pulp, crushing the passion fruit pulp and the pitaya flower respectively, mixing, adding 60-80% ethanol for extraction for 2 times, filtering, recovering ethanol from filtrate, and concentrating to obtain an extract with a relative density of 1.10-1.15/60 ℃ to obtain a composition extract A;
(2) separating water from the separated pulp by a freeze drying technology, controlling the total content of the residual water to be between 11 and 17 percent, repeatedly crushing the dried pulp into superfine powder by crushing, and sieving by a 500-mesh sieve to obtain fruit powder B for later use;
(3) uniformly mixing the fruit powder B, the natamycin and the xylo-oligosaccharide powder in parts by weight, sieving the mixture by a 500-mesh sieve, adding the honey, the lactose and the composition extract A, continuously stirring the mixture to fully mix the raw materials, repeatedly adding the composition extract A for 3 times to prepare soft material granules, drying the soft material granules at the drying temperature of 40-50 ℃ to obtain soft material granules with the water content of 10-15%, sieving the granules by a 20-30-mesh sieve, adding the magnesium stearate in parts by weight, uniformly tabletting, drying the tablets, controlling the temperature to be 40-50 ℃, controlling the tabletting weight to be 500-800 mg, and finally locking the water content to be below 5%.
6. The preparation method of the natamycin-containing health buccal tablet as claimed in claim 5, wherein the drying temperature of the passion fruit powder B extracted in the step (2) is controlled between-10 ℃ and-15 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910968051.6A CN110604296A (en) | 2019-10-12 | 2019-10-12 | Health buccal tablet containing natamycin and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910968051.6A CN110604296A (en) | 2019-10-12 | 2019-10-12 | Health buccal tablet containing natamycin and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110604296A true CN110604296A (en) | 2019-12-24 |
Family
ID=68894772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910968051.6A Pending CN110604296A (en) | 2019-10-12 | 2019-10-12 | Health buccal tablet containing natamycin and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110604296A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105614296A (en) * | 2014-10-27 | 2016-06-01 | 卢雨萍 | Passion fruit chewable tablet and production method thereof |
CN105616476A (en) * | 2014-11-29 | 2016-06-01 | 荣昌县康华金银花种植股份合作社 | Honeysuckle flower buccal tablet and preparation method thereof |
CN105815621A (en) * | 2015-01-08 | 2016-08-03 | 太原市智友汇科技有限公司 | Method for producing xylo-oligosaccharide sea-buckthorn whole fruit powder lozenge |
CN109480244A (en) * | 2018-12-22 | 2019-03-19 | 李瑞瑞 | A kind of passion fruit jam processing method |
-
2019
- 2019-10-12 CN CN201910968051.6A patent/CN110604296A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105614296A (en) * | 2014-10-27 | 2016-06-01 | 卢雨萍 | Passion fruit chewable tablet and production method thereof |
CN105616476A (en) * | 2014-11-29 | 2016-06-01 | 荣昌县康华金银花种植股份合作社 | Honeysuckle flower buccal tablet and preparation method thereof |
CN105815621A (en) * | 2015-01-08 | 2016-08-03 | 太原市智友汇科技有限公司 | Method for producing xylo-oligosaccharide sea-buckthorn whole fruit powder lozenge |
CN109480244A (en) * | 2018-12-22 | 2019-03-19 | 李瑞瑞 | A kind of passion fruit jam processing method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
CN105558617A (en) | Syzygium grijsii Merr. et Perry blood circulation activating and blood stasis removing pickled Chinese cabbage soup base and production method thereof | |
US9950024B2 (en) | Traditional Chinese medicine composition and the use thereof | |
CN104413333A (en) | Ginger-flavor red date-black sugar block | |
CN105533574A (en) | Toxin removing and body slimming green plum fruit and production technology thereof | |
CN106511641A (en) | Green plum and natto composition with gout treatment effect and preparation method thereof | |
CN109497227A (en) | A kind of brown sugar Qi jujube Health care ginger tea | |
CN102894272A (en) | Jasmine tea fragrant noodles | |
CN106070626A (en) | Koumiss fruit beverage and preparation method thereof | |
CN103518878B (en) | Honey vinegar beverage with function of lubricating intestines and invigorating stomach and preparation method thereof | |
CN101120706B (en) | Tea for morning-getting-up health-preserving | |
CN102293290B (en) | Tea capable of digesting and smoothing intestine and preparation method thereof | |
CN110637905A (en) | Substitutional tea for treating pharyngitis and preparation method thereof | |
CN112273490A (en) | Hawthorn and ginger tea potion | |
KR20180002158A (en) | A composition for removing hangover comprising an herb extract including ginseng | |
KR100503926B1 (en) | Compositions for inhibiting effect of growth of harmful bacteria | |
CN110604296A (en) | Health buccal tablet containing natamycin and preparation method thereof | |
CN104738749A (en) | Preparation method of pure natural nutritional immune health fruit juice | |
CN104605063A (en) | Preparation method for Hibiscus sabdariffa summer heat relieving tea bag | |
CN109673994B (en) | Sour papaya and chili jam and preparation method thereof | |
CN105495171A (en) | Viola inconspicua and pickled Chinese cabbage soup base capable of clearing heat and cooling blood and production method of viola inconspicua and pickled Chinese cabbage soup base | |
KR100707342B1 (en) | Functional food using mulberry, leek and white clay and a method for producing thereof | |
CN104473282B (en) | A kind of Rhizoma Zingiberis Recens vinegar beverage and preparation method thereof | |
CN109497228A (en) | A kind of brown sugar ginger tea and preparation method thereof | |
CN113786470B (en) | Traditional Chinese medicine composition for treating deficiency of both qi and blood, food containing traditional Chinese medicine composition and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191224 |